BriaCell Therapeutics Corp.
BCTXZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001610820
No open-market purchases or sales by BriaCell Therapeutics Corp. insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $61.7K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in BriaCell Therapeutics Corp. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 4
- +1 vs. Q3 2025
- Shares held
- 1.48M
- +558.0K (+60.7%) vs. Q3 2025
- Total value
- $433.9K
- +$122.7K (+39.4%) vs. Q3 2025
- New holders
- 1
- 0 more added
- Sold out
- 0
- 2 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCTXZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 5 | $61.7K |
| Q1 2026 | 4 | $198.5K |
| Q4 2025 | 4 | $433.9K |
| Q3 2025 | 3 | $311.2K |
| Q2 2025 | 3 | $1.21M |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding BriaCell Therapeutics Corp.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 666,600 | $193.3K | 0.17% | +666,600 | New |
| Heights Capital Management, Inc | 544,698 | $163.4K | 0.06% | 00.0% | Unchanged |
| Sabby Management, LLC | 265,964 | $77.2K | 0.64% | −108,524−29.0% | Reduced |
| UBS Group AG | 5 | $1 | 0.00% | −61−92.4% | Reduced |